Regulatory actions for Jan. 27, 2026

FierceBiotechAmgen loses in Harbour antibody patent case, ordered to pay $20M+

FierceBiotechIntellia touts ‘paradigm-shifting’ phase 3 data for one-time HAE treatment

FierceBiotechNeumora to lay off 35% of staff after navacaprant goes 0 for 3 in late-stage depression studies

Endpoints NewsNeumora drug fails two more Phase 3 trials, biotech to lay off 35% of staff

Clinical OMICsRewriting Cancer Care Through Epigenetics

FierceBiotechTraws defers midphase flu study after negative regulatory review

Endpoints NewsSix leaders working on LGBTQ+ inclusion in biopharma

BioWorldEnsem Therapeutics patents new GTPase KRAS mutant inhibitors

BioWorldCaregen reports new GLP-1R agonists

BioWorldIteos Belgium discloses new PTPN1/2 inhibitors

BioWorldJiangsu Aidea Pharmaceutical identifies amide compounds for HIV

BioWorldNew SOS1 inhibitors divulged in Sichuan Huiyu patent